Clinical Trial Evidence And Practical Differences Explained
What Is The Difference Between Wegovy And Mounjaro Mechanisms
When examining what is the difference between Wegovy and Mounjaro, the primary distinction lies in their receptor targeting mechanisms. Wegovy contains semaglutide, which acts as a GLP-1 receptor agonist, mimicking a natural hormone that promotes feelings of fullness and reduces appetite. Mounjaro contains tirzepatide, a dual agonist that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, potentially offering enhanced appetite suppression through this combined approach.
Both medications are administered as once-weekly subcutaneous injections using pre-filled FlexTouch pens, requiring dose escalation protocols under medical supervision. The dual receptor mechanism in Mounjaro may provide additional metabolic benefits, whilst Wegovy's single-target approach has extensive clinical data spanning multiple STEP trials. At EverydayMeds, our prescribers can assess which mechanism may be most appropriate for your individual weight management goals.
UK Weight Loss Results And Pricing Comparison
Understanding what is the difference between Wegovy and Mounjaro pricing helps inform treatment decisions alongside clinical considerations. Wegovy starts at £79.99 for the 0.25mg starter dose, escalating to £209.99 for the 2.4mg maintenance dose, with new customers using discount code FIRST40 at checkout. Our Intro Duo bundle (0.25mg & 0.5mg) provides the first 8 weeks of treatment for £169.99, offering convenience and Reliable Supply continuity.
Mounjaro pricing follows a different structure, with both treatments requiring similar dose escalation protocols over 16-20 weeks to reach therapeutic levels. Our 3-pen Ultimate Stability Trio provides three months of maintenance supply for £649.99, ensuring uninterrupted treatment during the crucial weight loss phase. Both medications are prescription-only medicines requiring clinical assessment through our GPhC-registered pharmacy (#9012878), with next-day cold-chain delivery included in all orders.
Clinical Evidence: What Is The Difference Between Wegovy And Mounjaro Trial Data
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated approximately clinically studied weight loss when combined with intensive behavioural therapy, whilst STEP 5 showed sustained clinically studied weight loss at two years.
Mounjaro's clinical evidence comes from the SURMOUNT trial programme, though direct head-to-head comparisons cannot be made due to different trial designs and patient populations. The SELECT cardiovascular outcomes trial showed Wegovy reduced major cardiovascular events by 20% in patients with established cardiovascular disease. Both medications require prescription alongside a reduced-calorie diet and increased physical activity to achieve optimal results.
How Wegovy Works: Understanding The Difference Between Wegovy And Mounjaro Action
Wegovy functions as a GLP-1 receptor agonist, binding to receptors in the brain's appetite control centres to promote satiety and reduce food cravings. This mechanism slows gastric emptying, meaning food remains in the stomach longer, creating prolonged feelings of fullness after smaller meals. The medication also influences the hypothalamic regions responsible for appetite regulation, potentially reducing the psychological drive to eat. Clinical studies suggest this dual peripheral and central action contributes to the sustained weight loss observed in the STEP trials. Unlike rapid-acting appetite suppressants, Wegovy's effects build gradually over the 16-week dose escalation period, allowing the body to adapt to reduced caloric intake naturally.
EverydayMeds Ordering Process For Both Treatments
Our streamlined ordering process makes accessing either Wegovy or Mounjaro straightforward and clinically safe. The journey begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any contraindications. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring each patient meets the licensed indication criteria for their chosen treatment. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. All shipments include detailed administration guidance, dose escalation schedules, and direct access to our clinical support team. This process ensures compliance with MHRA regulations whilst providing convenient access to prescription-only weight management treatments.
Storage Requirements: Practical Differences Between Wegovy And Mounjaro
Storage considerations reveal another key difference between these medications, particularly relevant for UK patients managing treatment during travel or lifestyle changes. Wegovy pens require refrigeration at 2-8°C before first use but can withstand room temperature storage below 30°C for up to 6 weeks once removed from refrigeration. Mounjaro offers similar refrigeration requirements but provides only 21 days of room temperature stability, making Wegovy more practical for extended travel or flexible storage needs. Both medications use the intuitive FlexTouch pen delivery system, with dose counters and safety mechanisms designed for self-administration. The pre-filled pens eliminate dosing errors common with vial-and-syringe systems, whilst the fine 32-gauge needles minimise injection discomfort during weekly administration.
What Is The Difference Between Wegovy And Mounjaro For UK Patients
For UK patients specifically, understanding what is the difference between Wegovy and Mounjaro extends beyond clinical mechanisms to practical healthcare access and ongoing support. Wegovy benefits from extensive NHS evaluation through NICE TA875, recommending its use within specialist weight management programmes, providing additional clinical confidence for prescribers and patients. The medication's established supply chain and proven storage stability make it particularly suitable for patients requiring consistent access without frequent pharmacy visits.
Mounjaro's newer market entry means evolving clinical guidelines and prescriber familiarity, though its dual-receptor mechanism represents an innovative approach to weight management pharmacotherapy. Both treatments require similar monitoring protocols, including regular weight assessments, blood pressure checks, and evaluation for gastrointestinal side effects. The choice between treatments often depends on individual patient factors, previous treatment responses, and prescriber clinical judgement rather than superiority of either medication.
Making Your Treatment Decision With EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, with your prescriber helping determine which treatment aligns with your individual circumstances and weight management goals. New customers can access their chosen treatment using discount code FIRST40, whilst returning patients benefit from code DOSE25 at checkout. Our clinical team provides ongoing support throughout your treatment journey, from initial assessment through dose escalation to maintenance therapy. Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment, with both treatments backed by our commitment to safe, effective weight management support. As a GPhC-registered UK pharmacy (#9012878), we ensure all treatments meet stringent quality standards whilst providing the convenience and discretion modern patients expect from their healthcare providers.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
